论文部分内容阅读
目的：与特拉唑嗪比较观察乌拉地尔治疗原发性高血压的降压疗效、不良反应。方法：采用随机、开放的方法，观察８０ 例符合 Ｗ Ｈ Ｏ 标准的Ⅰ、Ⅱ期高血压患者。乌拉地尔组５２ 例，６０ ～９０ ｍ ｇ／ｄ 。特拉唑嗪组２８ 例，１ ～８ ｍ ｇ／ｄ 。分早晚服药各１ 次。记录治疗前后血压、心率及不良反应。结果：乌拉地尔和特拉唑嗪显著降低原发性高血压患者的收缩压、舒张压，对心率无影响（ Ｐ＞ ０ ．０５） 。降压疗效比较，乌拉地尔的总有效率达８１ ％ ，特拉唑嗪为６４ ％ 。两组比较无明显差异性。乌拉地尔与特拉唑嗪不良反应的发生率较低，两组比较无差异性。结论：乌拉地尔治疗原发性高血压有显著疗效，无明显不良反应。
OBJECTIVE: To compare the antihypertensive effects and adverse reactions of urapidil in the treatment of essential hypertension with terazosin. Methods: A randomized and open method was used to observe 80 patients with stage I and II hypertension who meet the criteria of W H O. Urapidil group 52 cases, 60 ~ 90 m g / d. Terazosin group 28 cases, 1 ~ 8 m g / d. Sub-morning and evening medication 1 times. Record before and after treatment of blood pressure, heart rate and adverse reactions. Results: Urapidil and terazosin significantly reduced systolic and diastolic blood pressure in patients with essential hypertension without any effect on heart rate (P> 0.05). Antihypertensive efficacy comparison, the total effective rate of 81% urapidil, terazosin was 64%. No significant difference between the two groups. The incidence of adverse reactions to urapidil and terazosin was low, with no difference between the two groups. Conclusion: Urapidil is effective in treating essential hypertension with no obvious adverse reactions.